Journal Article

DKFZ-2022-02327

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png EVI1 expression in early-stage breast cancer patients treated with neoadjuvant chemotherapy.

Leichsenring, J. ; Vladimirova, V. ; Solbach, C. ; Karn, T. ; Ataseven, B. ; Sinn, B. V. ; Barinoff, J. ; Müller, V. ; Blohmer, J.-U. ; Schem, C. ; Engels, K. ; Marmé, F. ; Fisseler-Eckhoff, A. ; Fasching, P. A. ; Stickeler, E. ; van Mackelenbergh, M. ; Denkert, C. ; Stenzinger, A. ; Loibl, S. ; Gröschel, S. (Last author)DKFZ*

2022
Springer Heidelberg

This record in other databases:  

Please use a persistent id in citations: doi:10.1186/s12885-022-10109-1

Abstract: Overexpression of the EVI1 (ecotropic viral integration site 1) oncogene has recently been implicated as a prognostic factor in breast cancer (BC), particularly in triple-negative BC (TNBC). In this study we aimed to investigate frequency and clinical relevance of EVI1 expression in newly diagnosed BC treated with neoadjuvant chemotherapy.EVI1 expression was determined by immunohistochemistry using H-score as a cumulative measurement of protein expression in pretherapeutic biopsies of BC patients treated with anthracycline/taxane based neoadjuvant chemotherapy within the GeparTrio trial. EVI1 was analyzed as a continuous variable and dichotomized into low or high based on median expression. Endpoints were pathological complete response (pCR), disease-free survival (DFS) and overall survival (OS).Of the 993 tumors analyzed, 882 had available subtype information: 50.8% were HR + /HER2-, 15% HR + /HER2 + , 9.8% HR-/HER2 + , and 24.5% TNBC. Median EVI1 H-score was 112.16 (range 0.5-291.4). High EVI1 expression was significantly associated with smaller tumor size (p = 0.002) but not with BC subtype. Elevated EVI1 levels were not significantly associated with therapy response and survival in the entire cohort or within BC subtypes. However, TNBC patients with high EVI1 showed a trend towards increased pCR rates compared to low group (37.7% vs 27.5%, p = 0.114; odds ratio 1.60 (95%CI 0.90-2.85, p = 0.110) and numerically better DFS (HR = 0.77 [95%CI 0.48-1.23], log-rank p = 0.271) and OS (HR = 0.76 [95% 0.44-1.31], log-rank p = 0.314) without reaching statistical significance.EVI1 was not associated with response to neoadjuvant therapy or patient survival in the overall cohort. Further analyses are needed to verify our findings especially in the pathological work-up of early-stage HER2-negative BC patients.NCT00544765.

Keyword(s): Breast cancer ; EVI1 ; Neoadjuvant chemotherapy

Note: #LA:A380#

---

Contributing Institute(s):

1. NWG Molekulare Leukämogenese (A380)

Research Program(s):

1. 311 - Zellbiologie und Tumorbiologie (POF4-311) (POF4-311)

Appears in the scientific report 2022

---

Database coverage:
; ; ; Article Processing Charges ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; DOAJ Seal ; Ebsco Academic Search ; Essential Science Indicators ; Fees ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---